Media stories about Biostar Pharmaceuticals (NASDAQ:BSPM) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biostar Pharmaceuticals earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0869025241411 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Biostar Pharmaceuticals (NASDAQ:BSPM) traded up $0.07 during midday trading on Thursday, hitting $1.91. 40,100 shares of the stock were exchanged, compared to its average volume of 76,774. Biostar Pharmaceuticals has a 12 month low of $1.18 and a 12 month high of $4.30. The firm has a market capitalization of $4.85, a P/E ratio of 2.63 and a beta of 1.87.
Biostar Pharmaceuticals (NASDAQ:BSPM) last posted its quarterly earnings data on Wednesday, November 15th. The company reported ($0.50) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the business posted ($3.12) EPS.
Biostar Pharmaceuticals Company Profile
Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).
Receive News & Ratings for Biostar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.